(Q36384453)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16452996%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

review article

1 reference

title

Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16452996%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16452996%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Viberti G

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16452996%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

1 April 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16452996%20AND%20SRC:MED&resulttype=core&format=json

Journal of Human Hypertension

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16452996%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16452996%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16452996%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

239-253

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16452996%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.jhh.1001982

16 January 2020

exact match

0 references

cites work

Advancing nephrology around the globe: an invitation to contribute.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

How does angiotensin II cause renal injury?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Interactive nitric oxide-angiotensin II influences on renal microcirculation in angiotensin II-induced hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

The role of nitric oxide in the regulation of glomerular haemodynamics in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Blood pressure control, drug therapy, and kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Transforming growth factor-beta and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

GLUT-1 overexpression: Link between hemodynamic and metabolic factors in glomerular injury?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Acute hypertension activates mitogen-activated protein kinases in arterial wall

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Transforming growth factor beta in tissue fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Regression of renal vascular and glomerular fibrosis: role of angiotensin II receptor antagonism and matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

The role of angiotensin II and plasminogen activator inhibitor-1 in progressive glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Clinical importance of microalbuminuria in diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Diabetic renal disease: from recent studies to improved clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Preventing microalbuminuria in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: the NESTOR Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Long-term dual blockade with candesartan and lisinopril in hypertensive patients with diabetes: the CALM II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Dissociation between blood pressure reduction and fall in proteinuria in primary renal disease: a randomized double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

The verapamil versus amlodipine in nondiabetic nephropathies treated with trandolapril (VVANNTT) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLH

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Angiotensin II receptor blockers: the importance of dose in cardiovascular and renal risk reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic renal disease: safety issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

Pathophysiology of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

7 January 2021

Standards of medical care in diabetes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

7 January 2021

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

7 January 2021

Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

7 January 2021

Effects of blood pressure and antihypertensive treatment on progression of advanced chronic renal failure.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

7 January 2021

Renin-angiotensin blockade lowers MCP-1 expression in diabetic rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

7 January 2021

Elevated intraluminal pressure inhibits vascular tissue plasminogen activator secretion and downregulates its gene expression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

7 January 2021

Urinary Albumin Excretion Predicts Cardiovascular and Noncardiovascular Mortality in General Population

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

7 January 2021

The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

7 January 2021

Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

7 January 2021

Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

7 January 2021

Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

7 January 2021

Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

7 January 2021

Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

7 January 2021

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

7 January 2021

Comparative effects of different antihypertensive treatments on progression of diabetic renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

7 January 2021

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.JHH.1001982

7 January 2021